Blockchain Registration Transaction Record

Tonix Reports Q1 2026 Results, TONMYA Momentum Grows

Tonix Pharmaceuticals reports Q1 2026 results with strong TONMYA launch momentum, managed care coverage for 35M lives, and positive Phase 1 data for Lyme disease candidate TNX-4800.

The success of TONMYA and the expansion of its managed care coverage are critical for fibromyalgia patients who have had limited treatment options for 15 years. This news also signals potential breakthroughs in Lyme disease prevention and new applications for TONMYA in major depressive disorder, which could address major public health challenges. Investors should note the commercial traction and pipeline progress as key indicators of Tonix's growth trajectory.